<DOC>
	<DOCNO>NCT00038467</DOCNO>
	<brief_summary>To compare sequential administration exemestane administration tamoxifen 5 year postmenopausal woman operable breast cancer already receive 2-3 year adjuvant tamoxifen , term disease-free survival ( DFS ) , overall survival ( OS ) , incidence contralateral breast cancer long-term tolerability .</brief_summary>
	<brief_title>Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>postmenopausal woman histologically cytologically confirm primary breast adenocarcinoma , receive tamoxifen treat tamoxifen continuously 2 3 year one month , still free disease unresectable breast cancer ER negative primary tumor</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>